List of publications using KO143 (Axon 1409) purchased from Axon Medchem

(Total 8 publication citations listed from 2010 until 2018)

Mairinger, S., Zoufal, V., Wanek, T., Traxl, A., Filip, T., Sauberer, M., ... & Langer, O. (2018). Influence of breast cancer resistance protein and P-glycoprotein on tissue distribution and excretion of Ko143 assessed with PET imaging in mice. European Journal of Pharmaceutical Sciences, 115, 212-222.

Sabnis, N. G., Miller, A., Titus, M. A., & Huss, W. J. (2017). The efflux transporter ABCG2 maintains prostate stem cells. Molecular Cancer Research, 15(2), 128-140.

Savolainen, H., Windhorst, A. D., Elsinga, P. H., Cantore, M., Colabufo, N. A., Willemsen, A. T., & Luurtsema, G. (2017). Evaluation of [18F] MC225 as a PET radiotracer for measuring P-glycoprotein function at the blood–brain barrier in rats: Kinetics, metabolism, and selectivity. Journal of Cerebral Blood Flow & Metabolism, 37(4), 1286-1298.

Wanek, T., Kuntner, C., Bankstahl, J. P., Mairinger, S., Bankstahl, M., Stanek, J., ... & Löscher, W. (2012). A novel PET protocol for visualization of breast cancer resistance protein function at the blood–brain barrier. Journal of Cerebral Blood Flow & Metabolism, 32(11), 2002-2011.

Wanek, T., Kuntner, C., Bankstahl, J. P., Bankstahl, M., Stanek, J., Sauberer, M., ... & Langer, O. (2011). Inhibition of breast cancer resistance protein at the murine blood-brain barrier by Ko143 studied with [11 C] tariquidar and PET. In BMC pharmacology (Vol. 11, No. S2, p. A48). BioMed Central.

Martelli, A. M., Papa, V., Tazzari, P. L., Ricci, F., Evangelisti, C., Chiarini, F., ... & Pagliaro, P. (2010). Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK-and PP2A-dependent mechanisms. Leukemia, 24(4), 687-698.
* CI-1040 and KO143 from Axon Medchem

Chiarini, F., Grimaldi, C., Ricci, F., Tazzari, P. L., Evangelisti, C., Ognibene, A., ... & Pagliaro, P. (2010). Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer research, 70(20), 8097-8107.

Please wait...